Logo

Sotio Signs a Multiple Agreement with LegoChem Biosciences to Develop Novel Therapeutics for the Treatment of Solid Tumors

Share this

Sotio Signs a Multiple Agreement with LegoChem Biosciences to Develop Novel Therapeutics for the Treatment of Solid Tumors

Shots:

  • LCB to receive up front & milestone of ~$1027.5M upon achievement of development & regulatory milestones along with royalties on net sales. The deals also include ~$29.5M in upfront & milestones
  • Sotio to get rights to use LCB's ADC technology for 5 therapeutic programs targeting distinct tumor-associated antigens & will lead research, development, manufacturing & commercialization of ADC products. LCB will be responsible for the research activities & manufacturing of components related to its ConjuAll & linker-payload technologies
  • The agreement will combine SOTIO's antibodies with LCB's technologies with its multiple different payloads to deliver novel therapeutics for solid tumors

 Ref: Globe Newswire | Image: Sotio 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions